Bonus episode
Curious about what’s in store for the pharma industry in 2025? In this special episode of the EMJ GOLD podcast, Isabel and Jade are joined by three special guests who share their insights and hopes for the year ahead. The hosts also look back at last year’s predictions to see if any of them came true.
The line-up includes Jennifer Schranz of Ipsen, Mercedes Diz of Almirall and EMJ’s own Dr Jonathan Sackier – all of whom share their predictions in their areas of expertise.
A little more on GOLD’s guests…
Jennifer Schranz is the Senior Vice President, Global Head of Rare Diseases at Ipsen, where she oversees the Rare Diseases therapy area with a focus on R&D strategy and execution. During her time at the business, she has led talented teams of scientists and fostered strong internal collaborations within the company, leveraging her clinical development expertise to advance Ipsen’s vision of addressing challenging rare diseases.
Mercedes Diz has over 20 years’ experience in the pharmaceutical industry, having graduated with a degree in Biochemistry and Molecular Biology from the Autonomous University of Madrid. She has worked in a number of different pharmaceutical companies, from J&J to Pfizer, and is also a keen member of the Healthcare Businesswomen’s Association. At Almirall, she leads portfolio strategy and commercial innovation for global brands, new products and digital and cultural transformation.
Dr Jonathan Sackier is Chairman at EMJ and the host of the EMJ podcast, where he utilises his experience as a physician to discuss the latest breakthroughs and challenges in the medical field with fellow practitioners and experts. Jonathan is a founding partner of many start-ups in the medical technology space and created the world’s first operating room robot.
